ID   NCC-MFS3-C1
AC   CVCL_B3RM
DR   Wikidata; Q110433085
RX   PubMed=33990915;
WW   Provider; BizCom; -; https://en.cellline.jp/product/ncc-mfs3-c1/
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo, Tadashi).
CC   Doubling time: ~36 hours (PubMed=33990915).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Unspecified (PubMed=33990915).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Unspecified (PubMed=33990915).
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: In situ; Thigh, hypodermis; UBERON=UBERON_0000376+UBERON_0002072.
ST   Source(s): PubMed=33990915
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 10
ST   D16S539: 12,13
ST   D21S11: 30
ST   D5S818: 11
ST   D7S820: 10,11
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C6496; Myxofibrosarcoma
DI   ORDO; Orphanet_79105; Myxofibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   74Y
CA   Cancer cell line
DT   Created: 16-12-21; Last updated: 10-04-25; Version: 8
//
RX   PubMed=33990915; DOI=10.1007/s13577-021-00548-6;
RA   Tsuchiya R., Yoshimatsu Y., Noguchi R., Sin Y., Ono T., Sei A.,
RA   Takeshita F., Sugaya J., Iwata S., Yoshida A., Ohtori S., Kawai A.,
RA   Kondo T.;
RT   "Establishment and characterization of NCC-MFS3-C1: a novel
RT   patient-derived cell line of myxofibrosarcoma.";
RL   Hum. Cell 34:1266-1273(2021).
//